Clinical Trial

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Study acronym: LIBRETTO-531
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
Protocol Amendment History 79 amendments
This ClinicalTrials.gov record has been amended 79 times since 2019-12-24; most recent amendment 2026-03-02.
Status change: Completed → Active, Not Recruiting 2023-10-26
Status change: Active, Not Recruiting → Completed 2023-10-25
Status change: Recruiting → Active, Not Recruiting 2023-08-28
Status change: Not Yet Recruiting → Recruiting 2020-02-12
Trial Details
NCT Number NCT04211337
Lead Sponsor Loxo Oncology, Inc.
Collaborators: Eli Lilly and Company
Conditions Medullary Thyroid Cancer
Enrollment 291 participants
Start Date 2020-02-11
Primary Completion 2023-05-22 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-03-19